Report Description

United States Prostate Cancer Testing Market is expected to grow at an impressive rate during the forecast period, 2024-2028. The major factors include increasing prevalence of prostate cancer in men, increasing prostate cancer screening and testing, early diagnosis of prostate cancer and increasing interest of government in cancer testing and medical advancement. According to Global Cancer Observatory, in 2020, around 2281,658 new cancer cases were reported in the United States, among which 209,512 cases reported were of prostate cancer. Additionally, increasing awareness among public for early prostate diagnosis and detection is further expected to drive the growth of United States prostate cancer testing market.

The prostate gland's aberrant cells multiply and uncontrollably enlarge in men in prostate cancer. The tenth leading cause of mortality overall and the sixth major cause of death in men is prostate cancer. According to Statista, the United States leads among all countries across the globe in terms of spending on research and development, with expenditure exceeding around USD679.4 billion.

Rising prevalence of prostate cancer

In United States, prostate cancer is the most prevalent cancer in men. This is diagnosed in about 6 out of 10 men who are 65 years old and rare in men under 40 years. Prostate cancer is the second most common cancer among American males, after lung cancer. For instance, in the United States, it was predicted that about 268,490 new cases of prostate cancer were reported in 2022, up from 192,280 new cases in 2009. Moreover, it was estimated that in 2022 around 34,500 men would die of prostate cancer in the U.S.

Growing Geriatric Population

Globally, the cancer is the leading cause of death. According to American Society of Clinical Oncologists, prostate cancer is more than twice as likely in people over 70 years as compared to younger people. This is due to genetic disorder, unhealthy lifestyle, environment, radiations, physical carcinogens, chemical carcinogens as well as biological carcinogens. The need to develop testing procedures for cancer is expected to support the growth of US prostate cancer testing market.

Government Initiatives related to Prostate Cancer

The government provides funding for developing new technologies to enhance testing of prostate cancer positively. For instance, the National Cancer Institute initiated Prostate Specialized Programs of Research Excellence (SPORE)-a program designed to convert scientific findings into clinical settings-based outcomes. The institute also facilitates the development of new technologies and studies to gain a better understanding of monitoring, prevention, diagnosis, and treatment. Such initiatives are expected to drive the growth of United States Prostate Cancer Testing Market.

 

Technological Development

The techniques like prostate-specific antigen (PSA) testing which have developed over the years that confirm the tumor progression and proliferation have created new prospects for the growth of prostate cancer testing over the years. Moreover, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of testing methods. Additionally, most of the companies in the U.S. prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. This, in turn shows an impressive rate for the growth of the United States prostate cancer market.

Recent Developments

According to the Journal of the National Cancer Institute, in September 2022, a company namely Veracyte, Inc. announced the publishing of data to demonstrate that the company’s decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.

 Additionally, in June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. Due to this grant, the funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.


Download Free Sample Report

Market Segmentation

United States Prostate Cancer Testing Market can be segmented by biomarker type, application, end user, region and competitive landscape. Based on biomarker type, the market can be segmented into pre-biopsy/post-negative biopsy testing, initial evaluation: prostate-specific antigen (Total PSA, Free PSA), post-biopsy tissue testing. Based on application, the market can be segmented into diagnostics biomarkers, and prognostics biomarkers. In terms of end user, the market can be segmented into cancer research institutes, diagnostic laboratories, hospitals and clinics, ambulatory surgical center (ASCs), and others.

 Market Players

F. Hoffmann-La Roche Ltd (Foundation Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc. (Fujeribio) etc. are some of the leading companies operating in the market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Biomarker Type

Application

End User

Region

Company

Regional scope

 Northeast Region, Midwest Region, South Region, West Region

Key companies profiled

F. Hoffmann-La Roche Ltd (Foundation Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc. (Fujeribio)

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, United States Prostate Cancer Testing Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

         ·         United States Prostate Cancer Testing Market, By Biomarker Type

o    Pre-Biopsy/Post-Negative Biopsy Testing

o    Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)

o    Post-Biopsy Tissue Testing

         ·         United States Prostate Cancer Testing Market, By Application

o    )

o    Diagnostics Biomarkers

o    Prognostics Biomarkers

         ·         United States Prostate Cancer Testing Market, By End User

o    Cancer Research Institutes

o    Diagnostic Laboratories

o    Hospitals and Clinics

o    Ambulatory Surgical Center (ASCs)

o    Others

         ·         United States Prostate Cancer Testing Market, By Region:

o    Northeast

o    Midwest

o    South

o    West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States Prostate Cancer Testing Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

United States Prostate Cancer Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    1. Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    United States Prostate Cancer Testing Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.   By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue Testing)

5.2.2.   By Application (Diagnostics Biomarkers, Prognostics Biomarkers)

5.2.3.   By End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and Clinics, Ambulatory Surgical Center (ASCs), and Others)

5.2.4.   By Region (Northeast Region, Midwest Region, South Region, West Region)

5.2.5.     By Company (2022)

5.3.  Market Map

5.3.1.     By Biomarker Type

5.3.2.     By Application

5.3.3.     By End User

5.3.4.     By Region

6.    Northeast United States Prostate Cancer Testing Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Biomarker Type

6.2.2.     By Application

6.2.3.     By End User

7.    Midwest United States Prostate Cancer Testing Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Biomarker Type

7.2.2.     By Application

7.2.3.     By End User

8.    South United States Prostate Cancer Testing Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Biomarker Type

8.2.2.     By Application

8.2.3.     By End User

9.    West United States Prostate Cancer Testing Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Biomarker Type

9.2.2.     By Application

9.2.3.     By End User

10.  Market Dynamics

10.1.              Drivers

10.1.1.  Rising prevalence of prostate cancer

10.1.2.  Growing geriatric population

10.1.3.  Government Initiatives related to Prostate Cancer

10.1.4.  Technological Advancement

10.1.5.  Recent Development

10.2.              Challenges

10.2.1.  High Probability of False Positives during Prostate Cancer Testing

11.  Market Trends & Developments

12.  United States Economic Profile

13.  Competitive Landscape

13.1.              Business Overview

13.2.              Product Offerings

13.3.              Recent Developments

13.4.              Financials (As Reported)

13.5.              Key Personnel

13.5.1.                F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.).

13.5.2.                Siemens Healthcare GmbH

13.5.3.                OPKO Health, Inc. (GenPath)

13.5.4.                Myriad Genetics Inc.

13.5.5.                NeoGenomics Laboratories

13.5.6.                Danaher. (Beckman Coulter, Inc.)

13.5.7.                Agilent Technologies, Inc.

13.5.8.                Abcam plc.

13.5.9.                Bio-Techne. (ExoDx)

13.5.10.             H.U. Group Holdings, Inc. (Fujeribio)

14.  Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

United States Prostate Cancer Testing Market is expected to grow at an impressive rate by 2028 on account of increasing prevalence of prostate cancer.

down-arrow

By end user, the United States Prostate Cancer Testing Market is expected to be dominated by the hospitals & clinics segment due to change in lifestyle and prevalence of prostate cancer in men.

down-arrow

F. Hoffmann-La Roche Ltd (Foundation Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc. (Fujeribio) etc., are some of the leading players operating in United States Prostate Cancer Testing Market.

down-arrow

High probability of false positives results during prostate cancer testing is hindering the market growth in the United States.

profile

Sakshi Bajaal

Business Consultant
Press Release

United States Prostate Cancer Testing Market is Expected to be Dominated by Pre-Biopsy Testing Biomarker Type Through 2028

Feb, 2023

Rising incidence of prostate cancer is expected to drive the growth of the United States Prostate Cancer Testing Market in the forecast period, 2018-2028